Skip to main content

Pharvaris

DEUCRICTIBANT

Pharvaris is harnessing its established legacy in bradykinin B2 receptor science to advance investigational oral therapies for bradykinin-mediated angioedema.

Deucrictibant1,2

Deucrictibant is an orally administered bradykinin B2 receptor antagonist in development for the prevention and treatment of bradykinin-mediated angioedema attacks. Deucrictibant utilizes the same mechanism of action as icatibant, current standard-of-care for the on-demand treatment of HAE attacks.

Mechanism of Action1,2

Deucrictibant is a selective bradykinin B2 receptor antagonist that prevents the binding of bradykinin to the bradykinin B2 receptor, thereby blocking the activity of the main mediator responsible for AE-BK swelling.

Drug Properties1-13

In addition to utilizing the clinically-proven mechanism of action of antagonism of the bradykinin B2 receptor, deucrictibant also offers:

Oral bioavailability

Throughout the years, researchers have attempted to develop a bradykinin B2 receptor antagonist that could be delivered orally.3 As a small molecule, deucrictibant has high oral bioavailability.2

Selectivity2

Deucrictibant is highly selective to the bradykinin B2 receptor, resulting in virtually no off-target activity on the bradykinin B1 receptor.

Potency2

Deucrictibant is approximately 20-fold more potent than icatibant.
Two oral products with the same active ingredient, deucrictibant, are in development for the prevention and treatment of bradykinin-mediated angioedema attacks.2

DEUCRICTIBANT

EXTENDED RELEASE (XR)

Sustained absorption
In studies, deucrictibant maintained sustained therapeutic exposure over 24 hours from day one, allowing for once-daily oral treatment to prevent HAE attacks*2,17,18
  • Highly effective at preventing attacks*19,20
  • Potential for rapid and durable protection3
  • Well tolerated19,20
  • Once-daily oral administration2
Extended-Release (XR) Tablet18,23,24
The tablet formulation maintains matrix stability through the acid stomach environment, then begins to degrade when the pH in the gut and colon increases. This delayed release of drug substance from the tablet formulation, combined with deucrictibant’s colonic absorption, allows for an optimized plasma exposure profile for prophylaxis.
Pharmacokinetics/Pharmacodynamics
Deucrictibant XR achieves therapeutic exposure in approximately 1.5 hours, maintains therapeutic exposure for over 24 hours, and reaches steady state in 2-3 days, supporting its development and, upon regulatory approval, potential future use as a daily prophylactic treatment.

IMMEDIATE RELEASE (IR)

Rapid absorption
In studies, deucrictibant rapidly reaches therapeutic exposure within 15-30 minutes, allowing for on-demand oral treatment of HAE attacks6,11
  • Rapid onset of action22
  • Potential for single-capsule resolution10
  • Well tolerated10
  • Oral administration2
Immediate-Release (IR) Capsule6,21
The capsule formulation rapidly dissolves in the stomach to enable rapid (within 15-30 minutes) plasma exposure.
Pharmacokinetics/Pharmacodynamics
Deucrictibant IR maintains plasma exposure for >8 hours,4 supporting its development and, upon regulatory approval, potential future use as an on-demand treatment.
*To be confirmed with clinical data from Phase 3 studies
References

1. Lesage A, et al. Front Pharmacol. 2020;19:11:916; 2. Lesage A, et al. Int Immunopharmacol. 2022;105:108523; 3. Pharvaris, Data on file. Company Research; 4. Maurer M, et al. The Lancet Haematology. 2026;13, e200-e214; 5. Aygoren-Pursun E, et al. Lancet Hematol. 2026; 6. Maurer M, et al. Poster presented at: 2022 HAEi Global Leadership Workshop; Oct 6-9, 2022; Frankfurt, Germany; 7. Cicardi M, et al. N Engl J Med. 2010;363(6):532-541; 8. Maurer M, et al. IOS Study Group. Clin Exp Allergy. 2022;52(9):1048-1058; 9. Lesage A, et al. Presented at: 12th C1 Inhibitor Deficiency Angioedema Workshop; June 3-6, 2021; virtual; 10. Lesage A, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2020 Annual Meeting; Nov 13-15, 2020; virtual; 11. Maurer M, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting; Feb 24-27, 2023; San Antonio, TX, USA; 12. FIRAZYR (icatibant). US Prescribing information. Takeda; 01/2024; 13. Lesage A, et al. Presented at: International Drug Discovery Science & Technology (IDDST); May 22, 2024; Osaka, Japan; 14. Reshef A, et al. J Allergy Clin Immunol. 2024;154(2):398-411.e1; 15. Busse PJ and Christiansen SC. N Engl J Med. 2020;382(12):1136-1148; 16. Smith TD and Riedl MA. Ann Allergy Asthma Immunol. 2024;133(4):380-390; 17. Pharvaris. Data on file (Single-dose crossover PK study in healthy volunteers (n=14) under fasting conditions); 18. Zhang ZY, et al. Presented at: 14th C1 Inhibitor Deficiency and Angioedema Workshop; May 29-Jun 1, 2025; Budapest, Hungary; 19. Riedl MA, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting; Feb 23-26, 2024; Washington DC, USA; 20. Riedl MA, et al. Presented at: American College of Allergy, Asthma & Immunology (ACAAI); Nov 6-10, 2025; Orlando, FL, USA; 21. Maurer M, et al. Poster presented at: 2022 HAEi Global Leadership Workshop; Oct 6-9, 2022; Frankfurt, Germany; 22. Riedl MA, et al. Presented at: 14th C1 Inhibitor Deficiency and Angioedema Workshop; May 29-Jun 1, 2025; Budapest, Hungary; 23. Zhang ZY, et al. Presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 2026

Publications

Learn more about our scientific discoveries in our latest publications
EXPLORE PUBLICATIONS

Publications

Learn more about our scientific discoveries in our latest publications
EXPLORE PUBLICATIONS